Alcon announces fda approval of otc switch of pataday once daily relief

Alcon announces fda approval of the otc switch of pataday once daily relief extra strength.pataday® once daily relief extra strength(olopatadine 0.7%) is first and only eye allergy itch drop offering a full 24 hours of relief without a prescription in u.s..this formulation joins pataday® once daily relief (olopatadine 0.2%) and pataday® twice daily relief (olopatadine 0.1%), which were approved for sale over--counter in february 2020.pataday once daily relief extra strength (olopatadine 0.7%), formerly prescribed as pazeo®, will be available online beginning in september, ahead of national retail availability in early 2021.
ALC Ratings Summary
ALC Quant Ranking